Jan. 29, 2024 -- NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced achievement of operational requirements in NANORAY-312, an ongoing pivotal Phase 3 study evaluating potential first-in-class radioenhancer NBTXR3 for elderly patients with head and neck cancer, resulting in a $20M milestone payment from strategic partner Janssen

Financing was led by New Enterprise Associates (NEA) and closed with additional new investor Atlas Venture and continued investment by GV and F-Prime Capital Significant investment by top-tier syndicate endorses Comanche’s innovative science, notable clinical progress, and experienced team of siRNA and maternal health experts tackling the extraordinary unmet needs in preeclampsia Comanche’s lead siRNA drug candidate, CBP-4888, targets an underlying cause of preeclampsia: over-production of the p

The in-kind Target ALS Foundational grant will support the development of first-in-class condensate-modifying drugs (c-mods) targeting the TDP-43 condensatopathy in ALS animal model Jan. 16, 2024 -- Dewpoint Therapeutics Inc., a biotechnology company that translates the novel science of condensates into breakthrough therapeutics, today announced that it was awarded a Target ALS Foundation grant, in collaboration with the ALS Association and The Jackson Laboratory, for an in vivo proof-of-concep

Jan. 02, 2024 -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), announces it and its wholly-owned subsidiary, Verona Pharma, Inc. (the “Company”), have entered into a debt financing facility (“debt facility”) providing the Company with access to up to $400 million from funds managed by Oxford Finance LLC (“Oxford”) and Hercules Capital, Inc. (NYSE: HTGC) (“Hercules”) (collectively, the “Lenders”). The debt facility provides non-dilutive capital and further financial flexibility to support

Dec. 28, 2023 -- MedBright AI Investments Inc. (the “Company” or “MedBright”) (CSE:MBAI, OTCQB:MBAIF, FSE:1V7) today announced that further to its press releases dated September 8, 2023 and October 17, 2023, Vinergy Acquisition Corp., a wholly owned US subsidiary of MedBright (“MB Acquisition Co.”), has issued 350 common shares of MB Acquisition Co. (the “MBAC Shares”) to Mentorhead Incorporated, a Delaware corporation, dba Limmi (“Limmi”)‎ pursuant to the intellectual property license and opti

Medicovestor, Inc, a privately-held biopharmaceutical company focused on the development of novel antibody drug-conjugate (ADC) therapies, proudly announces the successful completion of its oversubscribed Seed financing round. This momentous achievement propels the company forward in advancing pioneering research, expanding its patent portfolio, and enhancing the capabilities of Medicovestor's two state-of-the-art ADC platforms. Founded by CEO Seah H Lim, MD, PhD, and fueled by a mission to res

Gradalis, Inc., a leader in the development of personalized anti-cancer cellular therapies for patients with solid tumors, announced today that it has been awarded a $9.9 million Product Development Research grant from the Cancer Prevention and Research Institute of Texas (CPRIT). The funds will be used to support the company's Phase 2 clinical study of Vigil® in platinum-sensitive patients who have recurrent ovarian cancer with a homologous recombination proficient (HRP) molecular profile. Thes

ViaNautis’s proprietary drug delivery platform polyNaut® is designed to deliver genetic therapeutic payloads across difficult-to-penetrate biological barriers, developing new medicines for diseases with unmet clinical need Series A led by 4BIO Capital, BGF, and UCB Ventures with participation from the Cystic Fibrosis Foundation, Eli Lilly and Company and existing investors including Origin Capital, Meltwind and O2H ViaNautis Bio (“ViaNautis” or the “Company”), a groundbreaking nanomedicine compa

AMN Healthcare (NYSE: AMN), the leader and innovator in total talent solutions for healthcare organizations across the United States, today announced a definitive agreement to acquire MSDR for a purchase price of $300 million. MSDR consists of two healthcare staffing companies that specialize in locum tenens and advanced practices, Medical Search International (MSI) and DRW Healthcare Staffing (DRW). MSI, founded in 2002, serves healthcare systems across the United States by placing high-qualit

Combined Company to Trade on Nasdaq Under Ticker “TRML” Talaris Announces 1-for-10 Reverse Stock Split of Common Stock Talaris Therapeutics, Inc. (Nasdaq: TALS) (“Talaris”) today announced the results of the special meeting of its stockholders held on October 17, 2023. At the special meeting, Talaris’ stockholders voted in favor of all proposals, including the proposal to approve the issuance of shares of Talaris’ common stock to the stockholders of Tourmaline Bio, Inc. (“Tourmaline”) pursuant t